Loading...
•
Sep 30, 2023
BioNano Q3 2023 Earnings Report
Bionano's Q3 2023 performance reflected revenue growth and strategic initiatives.
Key Takeaways
Bionano Genomics reported a 29% increase in revenue compared to Q3 2022, reaching $9.3 million. The company focused on expanding its installed base of Saphyr systems and increasing flowcell sales. Cost reduction initiatives were implemented to improve profitability.
Revenue increased by 29% compared to Q3 2022, reaching $9.3 million.
The installed base of Saphyr systems grew by 39% year-over-year, totaling 301 systems.
Flowcell sales increased by 55% compared to Q3 2022, with 6,176 flowcells sold.
The company completed an $80.0 million registered offering and concurrent private placement.
Revenue by Segment
Forward Guidance
Bionano reiterated its full year 2023 revenue guidance of $35.0 to $38.0 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...